German regenerative medicines capability show-cased at BIO

Germany presented itself as one of the world's leading regenerative medicine research locations at this year's BIO International Convention.  Under the "Breakthroughs in Regenerative Medicines in Germany" banner,  German experts provided an insight into the latest research results in  the area of regenerative medicine in the country.

Manfred Rudiger, chief executive of Frankfurt-based t2cure GmbH, and  Georg Duda, vice director of the Berlin-Brandenburg Center for  Regenerative Therapies  also spoke at the Germany Trade &  Invest-organized event. Both are experts and active partners in the  German research and enterprise landscape in the area of regenerative  medicine.

Regenerative medicine offers rich and varied potential at a time when  western social welfare states are confronted with the problem of rapidly  aging populations and overloaded health systems. It is generally  expected that not only should the quality of life of the patient be  improved by regenerative treatments, but also that health systems be  sustainably disburdened by eliminating protracted aftercare and  complications.